Drug Discovery 아웃소싱 시장(2024-2028년)

The drug discovery outsourcing market is forecasted to grow by USD 1.79 bn during 2023-2028, accelerating at a CAGR of 7.44% during the forecast period. The report on the drug discovery outsourcing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by robust demand for biosimilars, prioritization of core competencies, and an increased number of FDA-approved manufacturing facilities in developing nations.

Technavio's drug discovery outsourcing market is segmented as below:

By Product

• Small-molecules
• Biologics

By End-user

• Big pharmaceutical companies
• Small and medium-sized pharmaceutical companies
• Generic pharmaceutical companies

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the technological advancements boosting drug discovery outsourcing as one of the prime reasons driving the drug discovery outsourcing market growth during the next few years. Also, increased demand for regenerative medicine and cost reduction and efficiency-boosting demand for drug discovery outsourcing will lead to sizable demand in the market.

The report on the drug discovery outsourcing market covers the following areas:

• Drug discovery outsourcing market sizing
• Drug discovery outsourcing market forecast
• Drug discovery outsourcing market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading drug discovery outsourcing market vendors that include Aragen Life Sciences Pvt. Ltd., Aurigene Discovery Technologies, Catalent Inc., Charles River Laboratories International Inc., Curia Global Inc., Domainex, Eurofins Scientific SE, Evotec SE, GenScript Biotech Corp., LABORATORY CORPORATION OF AMERICA HOLDINGS, Lonza Group Ltd., Lupin Ltd., Novotech Health Holdings, Oncodesign Services, PerkinElmer Inc, QIAGEN NV, Shanghai Medicilon Inc., Syngene International Ltd., Thermo Fisher Scientific Inc., and WuXi AppTec Co. Ltd. Also, the drug discovery outsourcing market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview

2 Market Landscape

• 2.1 Market ecosystem

3 Market Sizing

• 3.1 Market definition
• 3.2 Market segment analysis
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

• 4.1 Global drug discovery outsourcing market 2018 - 2022
• 4.2 Product Segment Analysis 2018 - 2022
• 4.3 End-user Segment Analysis 2018 - 2022
• 4.4 Geography Segment Analysis 2018 - 2022
• 4.5 Country Segment Analysis 2018 - 2022

5 Five Forces Analysis

• 5.1 Five forces summary
• 5.2 Bargaining power of buyers
• 5.3 Bargaining power of suppliers
• 5.4 Threat of new entrants
• 5.5 Threat of substitutes
• 5.6 Threat of rivalry
• 5.7 Market condition

6 Market Segmentation by Product

• 6.1 Market segments
• 6.2 Comparison by Product
• 6.3 Small-molecules - Market size and forecast 2023-2028
• 6.4 Biologics - Market size and forecast 2023-2028
• 6.5 Market opportunity by Product

7 Market Segmentation by End-user

• 7.1 Market segments
• 7.2 Comparison by End-user
• 7.3 Big pharmaceutical companies - Market size and forecast 2023-2028
• 7.4 Small and medium-sized pharmaceutical companies - Market size and forecast 2023-2028
• 7.5 Generic pharmaceutical companies - Market size and forecast 2023-2028
• 7.6 Market opportunity by End-user

8 Customer Landscape

• 8.1 Customer landscape overview

9 Geographic Landscape

• 9.1 Geographic segmentation
• 9.2 Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• 9.4 Europe - Market size and forecast 2023-2028
• 9.5 Asia - Market size and forecast 2023-2028
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• 9.7 US - Market size and forecast 2023-2028
• 9.8 UK - Market size and forecast 2023-2028
• 9.9 Germany - Market size and forecast 2023-2028
• 9.10 Canada - Market size and forecast 2023-2028
• 9.11 Japan - Market size and forecast 2023-2028
• 9.12 Market opportunity By Geographical Landscape

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• 11.3 Landscape disruption
• 11.4 Industry risks

12 Vendor Analysis

• 12.1 Vendors covered
• 12.2 Market positioning of vendors
• 12.3 Aragen Life Sciences Pvt. Ltd.
• 12.4 Catalent Inc.
• 12.5 Charles River Laboratories International Inc.
• 12.6 Curia Global Inc.
• 12.7 Domainex
• 12.8 Eurofins Scientific SE
• 12.9 Evotec SE
• 12.10 GenScript Biotech Corp.
• 12.11 LABORATORY CORPORATION OF AMERICA HOLDINGS
• 12.12 Lonza Group Ltd.
• 12.13 Lupin Ltd.
• 12.14 Oncodesign Services
• 12.15 PerkinElmer Inc
• 12.16 QIAGEN NV
• 12.17 Thermo Fisher Scientific Inc.

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• 13.3 Currency conversion rates for US$
• 13.4 Research methodology
• 13.5 List of abbreviations